Nearly a Century of Insulin at Sanofi: Looking Back Over the Decades of Production and Development.

Clicks: 303
ID: 101274
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 5 articles by views in pediatric endocrinology reviews : per

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Almost a century ago, the first insulin was produced by Banting, Best, MacLeod and Collip in Toronto, thereby enabling life-saving treatment for people with diabetes. Since then, there have been many advancements in insulin production and development of new insulin analogues. In this article, we reflect on the rich heritage of Sanofi and its predecessor, Hoechst, in insulin production and development, from being one of the first companies to produce insulin in Europe in 1923, to modern-day insulin analogues and integrated care solutions at present-day Sanofi.
Reference Key
bosnyak2020nearlypediatric Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bosnyak, Zsolt;Korn, Marcus;Bielohuby, Maximilian;Wohlfart, Paulus;Tennagels, Norbert;
Journal pediatric endocrinology reviews : per
Year 2020
DOI
10.17458/per.vol17.2020.bkb.sanoficenturyinsulin
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.